CA3252955A1 - COMPOUNDS AND THEIR USES - Google Patents
COMPOUNDS AND THEIR USESInfo
- Publication number
- CA3252955A1 CA3252955A1 CA3252955A CA3252955A CA3252955A1 CA 3252955 A1 CA3252955 A1 CA 3252955A1 CA 3252955 A CA3252955 A CA 3252955A CA 3252955 A CA3252955 A CA 3252955A CA 3252955 A1 CA3252955 A1 CA 3252955A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- optionally substituted
- compound
- mhz
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340927P | 2022-05-11 | 2022-05-11 | |
| US63/340,927 | 2022-05-11 | ||
| PCT/US2023/021793 WO2023220219A1 (en) | 2022-05-11 | 2023-05-11 | Compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3252955A1 true CA3252955A1 (en) | 2023-11-16 |
Family
ID=86732694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3252955A Pending CA3252955A1 (en) | 2022-05-11 | 2023-05-11 | COMPOUNDS AND THEIR USES |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12139487B2 (https=) |
| EP (1) | EP4522280A1 (https=) |
| JP (2) | JP7531656B2 (https=) |
| KR (1) | KR20250024923A (https=) |
| CN (1) | CN119677738A (https=) |
| AR (1) | AR129299A1 (https=) |
| AU (1) | AU2023270055A1 (https=) |
| CA (1) | CA3252955A1 (https=) |
| CL (1) | CL2024003450A1 (https=) |
| CO (1) | CO2024015229A2 (https=) |
| DO (1) | DOP2024000231A (https=) |
| IL (1) | IL316531A (https=) |
| JO (1) | JOP20240250A1 (https=) |
| MX (1) | MX2024013838A (https=) |
| PE (1) | PE20250261A1 (https=) |
| TW (2) | TW202506693A (https=) |
| WO (1) | WO2023220219A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7675182B2 (ja) * | 2020-11-10 | 2025-05-12 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| CN121443603A (zh) * | 2023-07-05 | 2026-01-30 | 詹森药业有限公司 | 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1,6-萘啶化合物 |
| WO2025099307A1 (en) * | 2023-11-10 | 2025-05-15 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of diseases |
| WO2025193614A1 (en) * | 2024-03-11 | 2025-09-18 | Enanta Pharmaceuticals, Inc. | Fused heterobicyclic antiviral agents |
| WO2025209520A1 (zh) * | 2024-04-03 | 2025-10-09 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其用途 |
| WO2025237242A1 (zh) * | 2024-05-14 | 2025-11-20 | 上海和誉生物医药科技有限公司 | 一种smarca2抑制剂及其应用 |
| CN118930561B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种稠环化合物 |
| CN118930537B (zh) * | 2024-07-23 | 2025-05-13 | 上海信诺维生物医药有限公司 | 一种抑制brm的化合物 |
| CN118908980B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种多环化合物 |
| WO2026046365A1 (zh) * | 2024-08-30 | 2026-03-05 | 上海齐鲁制药研究中心有限公司 | Smarca2抑制剂及其制备方法和用途 |
| WO2026057002A1 (zh) * | 2024-09-12 | 2026-03-19 | 江苏恒瑞医药股份有限公司 | 一种烯炔类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101511840A (zh) | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物及其使用方法 |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
| RU2743074C2 (ru) | 2014-08-01 | 2021-02-15 | Нуэволюшон А/С | Соединения, активные по отношению к бромодоменам |
| CN115297861B (zh) * | 2020-01-29 | 2024-07-12 | 福宏治疗公司 | 化合物及其用途 |
| US20230121497A1 (en) * | 2020-01-29 | 2023-04-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CA3167275A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US20230149414A1 (en) * | 2020-01-29 | 2023-05-18 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| JP7675182B2 (ja) | 2020-11-10 | 2025-05-12 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
-
2023
- 2023-05-11 AR ARP230101168A patent/AR129299A1/es unknown
- 2023-05-11 TW TW113141340A patent/TW202506693A/zh unknown
- 2023-05-11 US US18/315,526 patent/US12139487B2/en active Active
- 2023-05-11 TW TW112117604A patent/TWI864749B/zh active
- 2023-05-11 CN CN202380053231.6A patent/CN119677738A/zh active Pending
- 2023-05-11 CA CA3252955A patent/CA3252955A1/en active Pending
- 2023-05-11 PE PE2024002469A patent/PE20250261A1/es unknown
- 2023-05-11 EP EP23729898.9A patent/EP4522280A1/en active Pending
- 2023-05-11 IL IL316531A patent/IL316531A/en unknown
- 2023-05-11 JP JP2023078608A patent/JP7531656B2/ja active Active
- 2023-05-11 AU AU2023270055A patent/AU2023270055A1/en active Pending
- 2023-05-11 KR KR1020247041093A patent/KR20250024923A/ko active Pending
- 2023-05-11 WO PCT/US2023/021793 patent/WO2023220219A1/en not_active Ceased
-
2024
- 2024-07-30 JP JP2024122975A patent/JP2024156779A/ja active Pending
- 2024-10-25 US US18/926,578 patent/US20250066354A1/en active Pending
- 2024-11-07 JO JOJO/P/2024/0250A patent/JOP20240250A1/ar unknown
- 2024-11-07 CO CONC2024/0015229A patent/CO2024015229A2/es unknown
- 2024-11-08 MX MX2024013838A patent/MX2024013838A/es unknown
- 2024-11-11 DO DO2024000231A patent/DOP2024000231A/es unknown
- 2024-11-11 CL CL2024003450A patent/CL2024003450A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20240250A1 (ar) | 2024-11-07 |
| TW202506693A (zh) | 2025-02-16 |
| CN119677738A (zh) | 2025-03-21 |
| AU2023270055A1 (en) | 2024-11-28 |
| US20250066354A1 (en) | 2025-02-27 |
| JP2023168298A (ja) | 2023-11-24 |
| DOP2024000231A (es) | 2024-12-15 |
| TW202411228A (zh) | 2024-03-16 |
| WO2023220219A1 (en) | 2023-11-16 |
| IL316531A (en) | 2024-12-01 |
| US12139487B2 (en) | 2024-11-12 |
| KR20250024923A (ko) | 2025-02-20 |
| CL2024003450A1 (es) | 2025-03-14 |
| PE20250261A1 (es) | 2025-01-29 |
| AR129299A1 (es) | 2024-08-07 |
| MX2024013838A (es) | 2025-03-07 |
| TWI864749B (zh) | 2024-12-01 |
| CO2024015229A2 (es) | 2025-03-06 |
| US20230365560A1 (en) | 2023-11-16 |
| JP7531656B2 (ja) | 2024-08-09 |
| JP2024156779A (ja) | 2024-11-06 |
| EP4522280A1 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12441726B2 (en) | Compounds and uses thereof | |
| US12139487B2 (en) | Compounds and uses thereof | |
| AU2021378949B2 (en) | Compounds and uses thereof | |
| JP7600396B2 (ja) | 化合物及びその使用 | |
| US20230079819A1 (en) | Compounds and uses thereof | |
| US20230150974A1 (en) | Compounds and uses thereof | |
| CA3216773A1 (en) | Compounds and uses thereof | |
| US20250304596A1 (en) | Pyrazine derivatives and uses thereof | |
| EP4522279A1 (en) | Pyrazine derivatives and uses thereof | |
| EA052989B1 (ru) | Соединения и их применение | |
| EA051512B1 (ru) | Соединения и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241108 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241108 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241108 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250207 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250207 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250207 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250318 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250326 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250402 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250408 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250408 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250424 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250424 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250506 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251208 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260407 |